Related resources and publications
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.
The humanized CD3ε mouse model was developed to express the human epitope of the CD3ε chain, which is recognized by T-cell engagers (clone SP34). The rest of the extracellular domain is murine to preserve the amino acids involved in the interaction with CD3γ and CD3δ.
Similarly, the transmembrane domains and the intracellular domains are murine to enable salt bridges’ interaction, interaction with the CD3ζ, and the signaling into mouse cells.
SP34 epitope of CD3ε is humanized. All other components of the CD3 complex are mouse.
(A) Diagram showing the co-expression of human CD3ε N-terminal epitope with mouse CD3 complex. (B) Splenocytes were isolated from wild-type and homozygous hCD3ε mice. Expression of CD3ε N-terminal human epitope recognized by the SP34.2, as well as expression of mouse CD3ε, was assessed using anti-human CD3 (clone SP342) and anti-mouse CD3 (clone 145-2C11), respectively, on single live splenocytes (n=3).
T-cell engagers efficacy assessment. (A) Experimental design for in vivo experiments. Tumor growth curves in (B) wild-type and (C) hCD3ε mice.
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
Let us know how we can help